View Older Stories View More Recent Stories
-
Intellia short interest rises most among biotech stocks in latest period - Baird
-
Iovance Biotherapeutics (IOVA) Misses Q1 EPS by 5c ; Offers Guidance
-
H.C. Wainwright Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
-
Jefferies on Iovanace Biotherapeutics (IOVA): 'we think the pot'l risk of competition was accounted for in Street models'
-
Citizens Upgrades Iovanace Biotherapeutics (IOVA) to Market Outperform
-
Iovance Biotherapeutics (IOVA) Misses Q4 EPS by 1c
-
Iovance reports 52% response rate for Amtagvi in early melanoma treatment
-
Iovance Biotherapeutics (IOVA) January 3 and 3.5 calls active as share price up 12.2%
-
Iovance reports 26% response rate in lung cancer trial
-
H.C. Wainwright Reiterates Buy Rating on Iovanace Biotherapeutics (IOVA)
-
Iovance receives Health Canada approval for melanoma cell therapy
-
Iovance Biotherapeutics (IOVA) Misses Q2 EPS by 5c, reiterates guidance
-
Barclays Reiterates Overweight Rating on Replimune Group (REPL), PT $17, 'We see this as a clear positive for Iovance's Amtagvi'
-
Citizens JMP Reiterates Market Perform Rating on Iovanace Biotherapeutics (IOVA)
-
Goldman Sachs Double Downgrades Iovanace Biotherapeutics (IOVA) to Sell
-
Iovance reports 49% response rate for Amtagvi in melanoma study
-
Iovance Biotherapeutics Sued for Securities Law Violations - Investors Should Contact Faruqi & Faruqi for More Information - IOVA
-
IOVA 3-DAY DEADLINE ALERT: Hagens Berman Reminds Iovance (IOVA) Investors of Pending Securities Class Action, Encourages Investors with Losses to Contact the Firm
-
IOVA COURT DEADLINE: Iovance Biotherapeutics Investors with Losses are Reminded to Contact BFA Law prior to the July 14 Class Action Deadline
-
IOVA DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 14 Deadline in Securities Class Acti
-
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
IOVA NOTIFICATION: Iovance Biotherapeutics Investors that Lost Money on their Investment are Notified to Contact BFA Law by July 14 Class Action Deadline
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
-
IOVA NOTIFICATION: Iovance Biotherapeutics Investors that Lost Money on their Investment are Notified to Contact BFA Law by July 14 Class Action Deadline
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
-
IOVA SHAREHOLDER ALERT: Iovance's (IOVA) CFO Resigns Amid Launch Setbacks and Legal Pressure- Hagens Berman
-
IOVA SHAREHOLDER NEWS: Iovance Biotherapeutics Investors that Incurred Losses are Urged to Contact BFA Law before the July 14 Class Action Deadline
-
IOVA DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action
-
IOVA SHAREHOLDER NOTICE: Iovance Biotherapeutics Investors are Notified to Contact BFA Law about the Pending Class Action Lawsuit by July 14
-
IOVA DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - IOV
-
Faruqi & Faruqi Reminds Iovance Biotherapeutics of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 14, 2025 - IOVA
-
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
IOVA CLASS ACTION NEWS: BFA Law Notifies Iovance Biotherapeutics Investors with Losses to Contact the Firm by July 14 Legal Deadline
-
IOVA 13-DAY DEADLINE ALERT: Iovance's (IOVA) Promising Cell Therapy Falters Triggering UBS Downgrades and Investor Lawsuit - Hagens Berman
-
IOVA Investors Have the Opportunity to Lead the Iovance Biotherapeutics Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
-
IOVA DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Act
-
IOVA CLASS NOTICE: Iovance Biotherapeutics Investors are Urged to Contact BFA Law before the Imminent July 14 Class Action Deadline
-
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
-
Scott+Scott Attorneys at Law LLP Alerts Investors of The Pending Class Action Against Iovance Biotherapeutics, Inc. (IOVA)
-
IOVA CLASS DEADLINE: Iovance Biotherapeutics Shareholders that Suffered Losses are Reminded to Contact BFA Law by Upcoming July 14 Court Deadline
-
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
-
IOVA FINAL DEADLINE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class
-
IOVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Iovance Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
-
Scott+Scott Attorneys at Law LLP Continues to Remind Investors of The Ongoing Securities Action Against Iovance Biotherapeutics, Inc. (IOVA)
-
IOVA DEADLINE ALERT: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Iovance Biotherapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securit
-
IOVA DEADLINE: BFA Law Reminds Iovance Biotherapeutics Investors with Losses to Submit their Information before July 14 Class Action Deadline
-
IOVA SECURITIES ALERT: Iovance Biotherapeutics Investors are Notified to Contact BFA Law before the Upcoming July 14 Class Action Deadline
-
Scott+Scott Attorneys at Law LLP Alerts Investors There Is an Ongoing Securities Action Against Iovance Biotherapeutics, Inc. (IOVA)
-
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Iovance Biotherapeutics
-
Iovance Biotherapeutics, Inc. Investors are Notified to Contact BFA Law by July 14 Deadline to Potentially Recover Losses in Securities Fraud Class Action
